Immunotherapy, first approved in 2011, uses the cancer patient’s own immune system to target and fight cancer. While it doesn’t work for everyone, for the 15% to 20% who do see results, it can be life-saving.
Like any medication, immunotherapy has the potential for adverse side effects — which can be severe for some. Studies show that some 10% to 15% of patients develop 'significant toxicities.' Headquartered in Chicago, GE HealthCare — working in tandem with Vanderbilt University Medical Center in Nashville, Tennessee — has created an AI model that's designed to help remove some of the uncertainties surrounding immunotherapy.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: